Eight in 10 now survive skin cancer

July 22, 2013, Cancer Research UK

(Medical Xpress)—More than eight out of 10 people diagnosed with malignant melanoma, the most dangerous form of skin cancer, will now survive the disease, compared to only around five in 10 in the early 70s, according to a new report from Cancer Research UK.

Ten year survival has reached 80 per cent in men and 90 per cent in women, compared to 38 per cent in men and 58 per cent in women 40 years ago. The improvements in are likely to be down to improvements in treatment, early and awareness of the symptoms.

Nearly 13,000 cases of melanoma are diagnosed each year in the UK, that's around 35 people every day.

Professor Richard Marais, director of the Cancer Research UK Paterson Institute for Cancer Research based at the University of Manchester, said: "Forty years ago, only around half of those diagnosed with were surviving, so eight out of 10 is a massive improvement. More and more people are beating skin cancer but we can't stop there and we need to develop better treatments for the two out of 10 where things don't look so good.

"Obviously we've come a long way in the fight against skin cancer and that's largely down to the of supporters who have funded research to help us to understand the disease better and find new ways of beating it. Research funded by Cancer Research UK has underpinned the development of new drugs like vemurafenib. Although these drugs do not cure skin cancers, they can give patients with advanced melanoma valuable extra months and show the progress we are making."

Dr Harpal Kumar, Cancer Research UK's chief executive, said: "Our research is revealing more about skin cancer: what causes it, how we can better prevent it and how we can develop targeted treatments to help more people beat the disease. By funding more research we can bring forward the day when even more people survive.

"Cancer Research UK research was behind the discovery that faults in a gene called BRAF contribute to over half of all cases of . Since then, our scientists have led efforts to develop drugs that target this gene.

"Skin cancer is one of the fastest rising cancers in the UK, which is likely to be down to our sunbathing habits and the introduction of cheap package holidays in previous decades. But the earlier cancer is detected, the easier it is to treat it and the more likely the treatment is to be successful. That's why it's important to get to know your skin and if you notice anything unusual, such as a change to a mole or a blemish that still hasn't healed after a few weeks, then get it checked out by your GP."

Explore further: Genome sequencing reveals mucosal melanoma's bullseye

More information: www.cancerresearchuk.org/cance … cerstats/types/skin/

Related Stories

Genome sequencing reveals mucosal melanoma's bullseye

June 7, 2013
(Medical Xpress)—Scientists may have found a molecular 'bullseye' for a rare form of melanoma, opening up opportunities for new targeted treatment, according to new research being published in the Journal of Pathology today ...

Early results show two drugs may be better than one to treat most deadly skin cancer

February 12, 2013
Adding lung cancer drugs to targeted melanoma treatment could increase survival for certain patients, according to research published in Cancer Discovery today.

Genetic screen finds new treatment targets for lung cancer

July 9, 2013
Cancer Research UK scientists are the first to use an efficient new screening strategy to identify gene faults in tumour cells that are possible drug targets for the most common form of lung cancer, according to new research ...

Shape-shifting cells help skin cancer spread

June 10, 2013
(Medical Xpress)—Scientists have discovered genes that control shape changes in melanoma skin cancer cells, allowing them to wriggle free and spread around the body, according to new research published in Nature Cell Biology.

Diabetes treatment doubles skin cancer drug's effectiveness

April 2, 2012
Combining the experimental drug Avastin (bevacizumab) with the diabetes drug Metformin almost doubles its ability to reduce skin cancer growth, according to a study in Cancer Discovery.

Study suggests patients should be screened before receiving vemurafenib

August 14, 2012
Different genetic mistakes driving skin cancer may affect how patients respond to the drug vemurafenib, providing grounds to screen people with melanoma skin cancer before treatment, a new study by Cancer Research UK scientists ...

Recommended for you

Two ways cancer resists treatment are actually connected, with one activating the other

December 18, 2018
Drugs that target BRAF and MEK in cancer have shown promise in treating a subset of melanoma that carries a mutation in the BRAF gene, but drug resistance usually emerges, reversing the benefit of these drugs and limiting ...

HPV discovery raises hope for new cervical cancer treatments

December 18, 2018
Researchers at the University of Virginia School of Medicine have made a discovery about human papillomavirus (HPV) that could lead to new treatments for cervical cancer and other cancers caused by the virus.

Vaccine, checkpoint drugs combination shows promise for pancreatic cancers

December 18, 2018
Researchers at the Johns Hopkins Kimmel Cancer Center discovered a combination of a cancer vaccine with two checkpoint drugs reduced pancreatic cancer tumors in mice, demonstrating a possible pathway for treatment of people ...

Researchers identify ways breast cancer avoids immune system detection

December 18, 2018
Recent breakthroughs in immunotherapy are making a huge difference in treating some forms of cancer, especially metastatic cancer. But breast cancer has proven a tricky foe for this new therapy, and an interdisciplinary team ...

Metal chemotherapy drugs boost the impact of immunotherapy in cancer

December 18, 2018
Due to their powerful tumour-killing effect, metal-based chemotherapies are frequently used in cancer treatment. However, it was hitherto assumed that they damaged the immune system, because of their cytotoxic (cell-damaging) ...

10-year follow-up after negative colonoscopies linked to lower colorectal cancer risk

December 17, 2018
Ten years after a negative colonoscopy, Kaiser Permanente members had 46 percent lower risk of being diagnosed with and were 88 percent less likely to die from colorectal cancer compared with those who did not undergo colorectal ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.